Q-omics provides the consensus-scored CDC37L1-DT profile across patient tissues and cancer cell-line models. CDC37L1-DT expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CDC37L1-DT is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, CDC37L1-DT RNA expression shows 16,202 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, KIRP, and THYM as cancer lineages where CDC37L1-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC37L1-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC37L1-DT survival associations across molecular data types. CDC37L1-DT RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC37L1-DT RNA expression–survival associations across cancer types. High CDC37L1-DT expression shows unfavorable associations in UCS and UVM, but favorable associations in MESO, OV, SKCM and LIHC. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CDC37L1-DT RNA expression.
This table summarizes CDC37L1-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CDC37L1-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC37L1-DT shows lower tumor expression in KIRP, KIRC, KICH, THCA, LUAD and BRCA. The KIRP box plot shows higher CDC37L1-DT RNA expression in normal versus tumor tissue (log2 FC = −1.104, t-test p < 0.001).
This table shows molecular features associated with CDC37L1-DT in patient tissues and cancer cell lines. In patient samples, CDC37L1-DT shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
